Effect of topical nepafenac in prevention of macular edema after cataract surgery in patients with non-proliferative diabetic retinopathy

Muhammad Haroon Sarfraz, Rana Intisar Ul Haq, Mohammad Asim Mehboob, Muhammad Haroon Sarfraz, Rana Intisar Ul Haq, Mohammad Asim Mehboob

Abstract

Objective: To determine the efficacy of topical Nepafenac (0.1%), administered post-operatively in prevention of Macular Edema (ME), after cataract surgery in patients with Non-Proliferative Diabetic Retinopathy (NPDR).

Methods: This randomized control trial was conducted at Armed Forces Institute of Ophthalmology (AFIO), Rawalpindi from Sep 2015 to Sep 2016. Sixty eyes of 60 patients with NPDR underwent phacoemulsification with intraocular lens implantation. Group 1 received 0.1% Nepafenac, 8-hourly, in operated eye after cataract surgery for three months, along with routine post-operative medications. Group-2 received only routine post-operative medications. ME was defined as increase in Central Macular Thickness (CMT) of >10% from pre-operative baseline, measured using spectral domain optical coherence tomography.

Results: Mean age of study population was 60.97±4.91 years. Out of 60 patients, 34 (56.7%) were males and 24 (43.3%) were females. Mean pre-operative CMT, 3 months post-operative CMT, mean change in CMT and mean frequency change in CMT of Group-1 was 226.5±10.86µm, 228.83±14.56 µm, 2.33±10.45 µm and 1.05% respectively. Mean pre-operative CMT, three months post-operative CMT, mean change in CMT and mean frequency change in CMT in Group-2 was 223.93±11.69µm, 236.17±16.16 µm, 12.23±12.40µm and 5.51% respectively. ME was observed in one patient (3.3%) in Group-1, and seven patients (23.3%) in Group 2. The difference of mean change in CMT and frequency change in CMT between groups was statistically significant (p<0.05).

Conclusion: 0.1% topical Nepafenac is effective in prevention of macular edema after cataract surgery in patients with non-proliferative diabetic retinopathy (NPDR).

Keywords: Cataract Surgery; Macular Edema; Nepafenac; Non-Proliferative Diabetic Retinopathy.

Conflict of interest statement

Declaration of interest: None.

References

    1. Manaviat MR, Oveisi N, Zare-Bidoki A. Accelerated bilateral cataract formation as a first manifestation of diabetes mellitus. Prague Med Rep. 2013;114:258–262.
    1. Kwon SI, Hwang DJ, Seo JY, Park IW. Evaluation of changes of macular thickness in diabetic retinopathy after cataract surgery. Korean J Ophthalmol. 2011;25:238–242. doi:10.3341/kjo.2011.25.4.238.
    1. Brito PN, Rosas VM, Coentrão LM, Carneiro ÂV, Rocha-Sousa A, Brandão E, et al. Evaluation of visual acuity, macular status, and subfoveal choroidal thickness changes after cataract surgery in eyes with diabetic retinopathy. Retina. 2015;35:294–302. doi:10.1097/IAE.0000000000000298.
    1. Kessel L, Tendal B, Jørgensen KJ, Erngaard D, Flesner P, Andresen JL, et al. Post-cataract prevention of inflammation and macular edema by steroid and nonsteroidal anti-inflammatory eye drops: a systematic review. Ophthalmology. 2014;121:1915–1924. doi:10.1016/j.ophtha.2014.04.035.
    1. Zaczek A, Artzen D, Laurell CG, Stenevi U, Montan P. Nepafenac 0.1% plus dexamethasone 0.1% versus dexamethasone alone: effect on macular swelling after cataract surgery. J Cataract Refract Surg. 2014;40:1498–1505. doi:10.1016/j.jcrs.2013.12.023.
    1. Lane SS. Nepafenac: a unique nonsteroidal prodrug. Int Ophthalmol Clin. 2006;46:13–20.
    1. Walters T, Raizman M, Ernest P, Gayton J, Lehmann R. In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg. 2007;33:1539–1545.
    1. Singh R, Alpern L, Jaffe GJ, Lehmann RP, Lim J, Reiser HJ, et al. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clin Ophthalmol. 2012;6:1259–1269. doi:10.2147/OPTH.S31902.
    1. Pašová P, Skorkovská K. The Effect of Cataract Surgery on the Reproducibility and Outcome of Optical Coherence Tomography Measurements of Macular and Retinal nerve Fibre Layer Thickness. Cesk Slov Oftalmol. 2016;72:20–26.
    1. Corrêa EP, Oliveira LF, Serracarbassa PD, Oshima A, Sousa e, Castro EF. Evaluation of macular edema after uncomplicated phacoemulsification surgery with implantation of intraocular lens by spectral domain optical coherence tomography. Arq Bras Oftalmol. 2013;76:357–362.
    1. Chu CJ, Johnston RL, Buscombe C, Sallam AB, Mohamed Q, Yang YC, United Kingdom Pseudophakic Macular Edema Study Group Risk Factors and Incidence of Macular Edema after Cataract Surgery: A Database Study of 81984 Eyes. Ophthalmology. 2016;123:316–323. doi:10.1016/j.ophtha.2015.10.001.
    1. Chen XY, Song WJ, Cai HY, Zhao L. Macular edema after cataract surgery in diabetic eyes evaluated by optical coherence tomography. Int J Ophthalmol. 2016;9:81–85. doi:10.18240/ijo.2016.01.14.
    1. Gallego-Pinazo R, Dolz-Marco R, Berrocal M, Wu L, Maia M, Serrano M, et al. Pan-American Collaborative Retina Study Group (PACORES) Outcomes of cataract surgery in diabetic patients: results of the Pan American Collaborative Retina Study Group. Arq Bras Oftalmol. 2014;77:355–359. doi:10.5935/0004-2749.20140089.
    1. Tsilimbaris M, Diakonis VF, Kymionis GD, Eleftheriadou MI, Fragkiskou S, Moschandreas J, et al. Prospective study of foveal thickness alterations after cataract surgery assessed by optical coherence tomography. Ophthalmologica. 2012;228:53–58. doi:10.1159/000336908.
    1. Katsimpris JM, Petropoulos IK, Zoukas G, Patokos T, Brinkmann CK, Theoulakis PE. Central foveal thickness before and after cataract surgery in normal and in diabetic patients without retinopathy. Klin Monbl Augenheilkd. 2012;229:331–337. doi:10.1055/s-0031-1299215.
    1. Kim SJ, Equi R, Bressler NM. Analysis of macular edema after cataract surgery in patients with diabetes using optical coherence tomography. Ophthalmology. 2007;114:881–889.
    1. Giocanti-Aurégan A, Grenet T, Fajnkuchen F, Chaine G. Impact of cataract surgery on central macular thickness in diabetic patients without diabetic retinopathy. J Fr Ophtalmol. 2013;36:35–40. doi:10.1016/j.jfo.2012.03.008.
    1. Diabetic Retinopathy Clinical Research Network Authors/Writing Committee. Baker CW, Almukhtar T, Bressler NM, Glassman AR, Grover S, et al. Macular edema after cataract surgery in eyes without preoperative central-involved diabetic macular edema. JAMA Ophthalmol. 2013;131:870–879. doi:10.1001/jamaophthalmol.2013.2313.
    1. Cervantes-Coste G, Sánchez-Castro YG, Orozco-Carroll M, Mendoza-Schuster E, Velasco-Barona C. Inhibition of surgically induced miosis and prevention of postoperative macular edema with nepafenac. Clin Ophthalmol. 2009;3:219–226.
    1. Nardi M, Lobo C, Bereczki A, Cano J, Zagato E, Potts S, et al. Analgesic and anti-inflammatory effectiveness of nepafenac 0.1% for cataract surgery. Clin Ophthalmol. 2007;1:527–533.
    1. Bucci FA, Jr, Waterbury LD. Prostaglandin E2 inhibition of ketorolac 0.45%, bromfenac 0.09%, and nepafenac 0.1% in patients undergoing phacoemulsification. Adv Ther. 2011;28:1089–1095. doi:10.1007/s12325-011-0080-7.
    1. Elsawy MF, Badawi N, Khairy HA. Prophylactic postoperative ketorolac improves outcomes in diabetic patients assigned for cataract surgery. Clin Ophthalmol. 2013;7:1245–1249. doi:10.2147/OPTH.S39188.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa